Insulin infusion reduces hepatocyte growth factor in lean humans

Barbora De Courten, Maximilian P J De Courten, Sonia Dougherty, Josephine M. Forbes, Jenna R. Potts, Robert Considine

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Plasma Hepatocyte Growth Factor (HGF) is significantly elevated in obesity and may contribute to vascular disease, metabolic syndrome or cancer in obese individuals. The current studies were done to determine if hyperinsulinemia increases plasma HGF. Materials/Methods: Twenty-two participants (10 women/12 men, BMI 20.6-34.5 kg/m2, age 18-49 years) underwent a hyperinsulinemic euglycemic clamp with measurement of HGF at baseline and steady state. Relationships between baseline HGF, anthropometrics, triglycerides, liver enzymes, c-reactive protein and adiponectin were also evaluated. Results: Fasting HGF was positively correlated (P < 0.050) with weight (r = 0.63), BMI (r = 0.55), waist circumference (r = 0.68), WHR (r = 0.48), triglycerides (r = 0.44), alanine aminotransferase (r = 0.74) and γ-glutamyl transpeptidase (r = 0.56), but not c-reactive protein or adiponectin. In stepwise regression, alanine aminotransferase and insulin sensitivity accounted for significant variation in fasting HGF. A significant effect of insulin to suppress HGF during the clamp (P = 0.029) was found after adjustment for BMI. HGF was reduced 7% at steady state in the lean subjects only (437.1 ± 57.8 vs 405.4 ± 72.0 pg/ml; P = 0.030). Conclusions: The positive correlation of HGF with hepatic enzymes suggests liver may be a significant source of circulating HGF in lean subjects. The strong correlation of plasma HGF with adiposity and the lack of an effect of insulin to increase HGF during the clamp in obese subjects suggest that adiposity, rather than elevated insulin levels, may be the major contributor to plasma HGF in obese subjects. Thus, a reduction in plasma HGF through weight loss is likely the best way to decrease comorbidities mediated by this angiogenic and mitogenic factor.

Original languageEnglish
Pages (from-to)647-650
Number of pages4
JournalMetabolism: Clinical and Experimental
Volume62
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Hepatocyte Growth Factor
Insulin
Adiponectin
Adiposity
Alanine Transaminase
Liver
Fasting
Triglycerides
Glucose Clamp Technique
gamma-Glutamyltransferase
Angiogenesis Inducing Agents
Hyperinsulinism
Waist Circumference
Enzymes
Vascular Diseases
Insulin Resistance
Comorbidity
Weight Loss

Keywords

  • Adipose tissue
  • Hyperinsulinemic-euglycemic clamp
  • Obesity

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

De Courten, B., De Courten, M. P. J., Dougherty, S., Forbes, J. M., Potts, J. R., & Considine, R. (2013). Insulin infusion reduces hepatocyte growth factor in lean humans. Metabolism: Clinical and Experimental, 62(5), 647-650. https://doi.org/10.1016/j.metabol.2012.10.013

Insulin infusion reduces hepatocyte growth factor in lean humans. / De Courten, Barbora; De Courten, Maximilian P J; Dougherty, Sonia; Forbes, Josephine M.; Potts, Jenna R.; Considine, Robert.

In: Metabolism: Clinical and Experimental, Vol. 62, No. 5, 05.2013, p. 647-650.

Research output: Contribution to journalArticle

De Courten, B, De Courten, MPJ, Dougherty, S, Forbes, JM, Potts, JR & Considine, R 2013, 'Insulin infusion reduces hepatocyte growth factor in lean humans', Metabolism: Clinical and Experimental, vol. 62, no. 5, pp. 647-650. https://doi.org/10.1016/j.metabol.2012.10.013
De Courten, Barbora ; De Courten, Maximilian P J ; Dougherty, Sonia ; Forbes, Josephine M. ; Potts, Jenna R. ; Considine, Robert. / Insulin infusion reduces hepatocyte growth factor in lean humans. In: Metabolism: Clinical and Experimental. 2013 ; Vol. 62, No. 5. pp. 647-650.
@article{882a350c21f84f9d8bea5e8e1911213d,
title = "Insulin infusion reduces hepatocyte growth factor in lean humans",
abstract = "Objective: Plasma Hepatocyte Growth Factor (HGF) is significantly elevated in obesity and may contribute to vascular disease, metabolic syndrome or cancer in obese individuals. The current studies were done to determine if hyperinsulinemia increases plasma HGF. Materials/Methods: Twenty-two participants (10 women/12 men, BMI 20.6-34.5 kg/m2, age 18-49 years) underwent a hyperinsulinemic euglycemic clamp with measurement of HGF at baseline and steady state. Relationships between baseline HGF, anthropometrics, triglycerides, liver enzymes, c-reactive protein and adiponectin were also evaluated. Results: Fasting HGF was positively correlated (P < 0.050) with weight (r = 0.63), BMI (r = 0.55), waist circumference (r = 0.68), WHR (r = 0.48), triglycerides (r = 0.44), alanine aminotransferase (r = 0.74) and γ-glutamyl transpeptidase (r = 0.56), but not c-reactive protein or adiponectin. In stepwise regression, alanine aminotransferase and insulin sensitivity accounted for significant variation in fasting HGF. A significant effect of insulin to suppress HGF during the clamp (P = 0.029) was found after adjustment for BMI. HGF was reduced 7{\%} at steady state in the lean subjects only (437.1 ± 57.8 vs 405.4 ± 72.0 pg/ml; P = 0.030). Conclusions: The positive correlation of HGF with hepatic enzymes suggests liver may be a significant source of circulating HGF in lean subjects. The strong correlation of plasma HGF with adiposity and the lack of an effect of insulin to increase HGF during the clamp in obese subjects suggest that adiposity, rather than elevated insulin levels, may be the major contributor to plasma HGF in obese subjects. Thus, a reduction in plasma HGF through weight loss is likely the best way to decrease comorbidities mediated by this angiogenic and mitogenic factor.",
keywords = "Adipose tissue, Hyperinsulinemic-euglycemic clamp, Obesity",
author = "{De Courten}, Barbora and {De Courten}, {Maximilian P J} and Sonia Dougherty and Forbes, {Josephine M.} and Potts, {Jenna R.} and Robert Considine",
year = "2013",
month = "5",
doi = "10.1016/j.metabol.2012.10.013",
language = "English",
volume = "62",
pages = "647--650",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Insulin infusion reduces hepatocyte growth factor in lean humans

AU - De Courten, Barbora

AU - De Courten, Maximilian P J

AU - Dougherty, Sonia

AU - Forbes, Josephine M.

AU - Potts, Jenna R.

AU - Considine, Robert

PY - 2013/5

Y1 - 2013/5

N2 - Objective: Plasma Hepatocyte Growth Factor (HGF) is significantly elevated in obesity and may contribute to vascular disease, metabolic syndrome or cancer in obese individuals. The current studies were done to determine if hyperinsulinemia increases plasma HGF. Materials/Methods: Twenty-two participants (10 women/12 men, BMI 20.6-34.5 kg/m2, age 18-49 years) underwent a hyperinsulinemic euglycemic clamp with measurement of HGF at baseline and steady state. Relationships between baseline HGF, anthropometrics, triglycerides, liver enzymes, c-reactive protein and adiponectin were also evaluated. Results: Fasting HGF was positively correlated (P < 0.050) with weight (r = 0.63), BMI (r = 0.55), waist circumference (r = 0.68), WHR (r = 0.48), triglycerides (r = 0.44), alanine aminotransferase (r = 0.74) and γ-glutamyl transpeptidase (r = 0.56), but not c-reactive protein or adiponectin. In stepwise regression, alanine aminotransferase and insulin sensitivity accounted for significant variation in fasting HGF. A significant effect of insulin to suppress HGF during the clamp (P = 0.029) was found after adjustment for BMI. HGF was reduced 7% at steady state in the lean subjects only (437.1 ± 57.8 vs 405.4 ± 72.0 pg/ml; P = 0.030). Conclusions: The positive correlation of HGF with hepatic enzymes suggests liver may be a significant source of circulating HGF in lean subjects. The strong correlation of plasma HGF with adiposity and the lack of an effect of insulin to increase HGF during the clamp in obese subjects suggest that adiposity, rather than elevated insulin levels, may be the major contributor to plasma HGF in obese subjects. Thus, a reduction in plasma HGF through weight loss is likely the best way to decrease comorbidities mediated by this angiogenic and mitogenic factor.

AB - Objective: Plasma Hepatocyte Growth Factor (HGF) is significantly elevated in obesity and may contribute to vascular disease, metabolic syndrome or cancer in obese individuals. The current studies were done to determine if hyperinsulinemia increases plasma HGF. Materials/Methods: Twenty-two participants (10 women/12 men, BMI 20.6-34.5 kg/m2, age 18-49 years) underwent a hyperinsulinemic euglycemic clamp with measurement of HGF at baseline and steady state. Relationships between baseline HGF, anthropometrics, triglycerides, liver enzymes, c-reactive protein and adiponectin were also evaluated. Results: Fasting HGF was positively correlated (P < 0.050) with weight (r = 0.63), BMI (r = 0.55), waist circumference (r = 0.68), WHR (r = 0.48), triglycerides (r = 0.44), alanine aminotransferase (r = 0.74) and γ-glutamyl transpeptidase (r = 0.56), but not c-reactive protein or adiponectin. In stepwise regression, alanine aminotransferase and insulin sensitivity accounted for significant variation in fasting HGF. A significant effect of insulin to suppress HGF during the clamp (P = 0.029) was found after adjustment for BMI. HGF was reduced 7% at steady state in the lean subjects only (437.1 ± 57.8 vs 405.4 ± 72.0 pg/ml; P = 0.030). Conclusions: The positive correlation of HGF with hepatic enzymes suggests liver may be a significant source of circulating HGF in lean subjects. The strong correlation of plasma HGF with adiposity and the lack of an effect of insulin to increase HGF during the clamp in obese subjects suggest that adiposity, rather than elevated insulin levels, may be the major contributor to plasma HGF in obese subjects. Thus, a reduction in plasma HGF through weight loss is likely the best way to decrease comorbidities mediated by this angiogenic and mitogenic factor.

KW - Adipose tissue

KW - Hyperinsulinemic-euglycemic clamp

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=84876680089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876680089&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2012.10.013

DO - 10.1016/j.metabol.2012.10.013

M3 - Article

C2 - 23190875

AN - SCOPUS:84876680089

VL - 62

SP - 647

EP - 650

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 5

ER -